Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ: ANIP) will be reporting earnings this Thursday before market open. Here’s what investors should know.
ANI Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $266 million, up 25.9% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance slightly missing analysts’ expectations.
Is ANI Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting ANI Pharmaceuticals’s revenue to grow 22.3% year on year, slowing from the 53.6% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. ANI Pharmaceuticals has a history of exceeding Wall Street’s expectations.
Looking at ANI Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 10%, beating analysts’ expectations by 6.3%, and Eli Lilly reported revenues up 38.6%, topping estimates by 7.9%. Eli Lilly traded up 9.8% following the results.
Read our full analysis of Amneal’s results here and Eli Lilly’s results here.
There has been positive sentiment among investors in the pharmaceuticals segment, with share prices up 2.8% on average over the last month. ANI Pharmaceuticals’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $105.78 (compared to the current share price of $72.23).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
